{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:57:31Z","timestamp":1791381451931,"version":"4.3.3"},"reference-count":21,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Ustekinumab, an IL-12\/IL-23 inhibitor with an established safety profile, has recently been associated with paradoxical cutaneous immune reactions. Amongst these, morphoea developing during therapy represents a rare but mechanistically relevant phenomenon that highlights cytokine imbalance in skin homeostasis. We performed a systematic review of published cases of morphoea occurring in patients treated with ustekinumab to better define their clinical and therapeutic patterns, and coupled it to the description of a new case of morphoea in a patient receiving ustekinumab for Beh\u00e7et disease. A search of PubMed, Web of Science and SciELO through October 2025 identified six eligible reports. Patients (median age 55.5 years) received ustekinumab for psoriasis, psoriatic arthritis or inflammatory bowel disease. Morphoea developed after 6\u201364 months of treatment and presented exclusively as plaque-type lesions with one showing overlap with lichen sclerosus. Discontinuation of ustekinumab led to improvement or remission in most patients, whilst continued therapy was associated with progression in one case. The temporal pattern, morphology and response to withdrawal support a drug-related effect, potentially reflecting a shift from a T helper 1 (TH1)\/TH17 pathway towards profibrotic TH2 and TGF\u03b2 pathways. Interpretation is limited by the very small number of published cases, heterogeneity of clinical descriptions, and lack of standardized diagnostic or therapeutic criteria, restricting firm causal inference. Despite these limitations, awareness of this paradoxical reaction is important for timely recognition and management. Further mechanistic investigation and pharmacovigilance are needed.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summary-ustekinumab-associated-morphoea-systematic-review-of-the-literature-and-a-real-world-case<\/jats:p>","DOI":"10.7573\/dic.2025-11-1","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:25:02Z","timestamp":1770035102000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Ustekinumab-associated morphoea: systematic review of the literature and a real-world case"],"prefix":"10.7573","author":[{"given":"Marco","family":"Sousa","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/056gkfq80","id-type":"ROR","asserted-by":"publisher"}],"name":"Unidade Local de Sa\u00fade de Santo Ant\u00f3nio EPE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel","family":"Alvarenga","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/056gkfq80","id-type":"ROR","asserted-by":"publisher"}],"name":"Unidade Local de Sa\u00fade de Santo Ant\u00f3nio EPE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"L\u00e9","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/056gkfq80","id-type":"ROR","asserted-by":"publisher"}],"name":"Unidade Local de Sa\u00fade de Santo Ant\u00f3nio EPE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/056gkfq80","id-type":"ROR","asserted-by":"publisher"}],"name":"Unidade Local de Sa\u00fade de Santo Ant\u00f3nio EPE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tBenson JM, Sachs CW, Treacy G, Zhou H, Pendley CE, Brodmerkel CM, Shankar G, Mascelli MA. Therapeutic targeting of the IL-12\/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol. 2011;29(7): 615\u2013624. https:\/\/doi.org\/10.1038\/nbt.1903","DOI":"10.1038\/nbt.1903"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tOtani IM, Levin AS, Banerji A. Cutaneous manifestations of reactions to biologics. Curr Allergy Asthma Rep. 2018;18(2):12. https:\/\/doi.org\/10.1007\/s11882-018-0764-z","DOI":"10.1007\/s11882-018-0764-z"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tMaliyar K, Mufti A, Sachdeva M, Lytvyn Y, Salsberg J, Yeung J. Development of morphea in patients receiving biologic therapies: a systematic review. J Am Acad Dermatol. 2021;84(4):1081\u20131085. https:\/\/doi.org\/10.1016\/ j.jaad.2020.06.1027","DOI":"10.1016\/j.jaad.2020.06.1027"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tFett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011;64(2):217\u2013228. https:\/\/doi.org\/10.1016\/j.jaad.2010.05.045","DOI":"10.1016\/j.jaad.2010.05.045"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tSteuer AB, Peterson E, Lo Sicco K, et al. Morphea in a patient undergoing treatment with ustekinumab. JAAD Case Rep. 2019;5(7):590\u2013592. https:\/\/doi.org\/10.1016\/j.jdcr.2019.05.008","DOI":"10.1016\/j.jdcr.2019.05.008"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tCirone K, Vender R. Plaque psoriasis and morphea in a patient on ustekinumab: a case report. SAGE Open Med Case Rep. 2023;11:2050313X231164207. https:\/\/doi.org\/10.1177\/2050313X231164207","DOI":"10.1177\/2050313X231164207"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tMetko D, Mehta S, Vender R. Morphea in patients with psoriasis treated with ustekinumab: a scoping review. Arch Dermatol Res. 2024;316(8):492. https:\/\/doi.org\/10.1007\/s00403-024-03236-1","DOI":"10.1007\/s00403-024-03236-1"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tMakihara-Inukai M, Takeichi T, Ogawa-Momohara M, Muro Y, Akiyama M. Morphea in a Crohn\u2019s disease patient undergoing ustekinumab treatment. Eur J Dermatol. 2021;31(1):96\u201397. https:\/\/doi.org\/10.1684\/ejd.2020.3956","DOI":"10.1684\/ejd.2020.3956"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tPage MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tMoola S, Munn Z, Tufanaru C, et al. Systematic reviews of etiology and risk. In: Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, eds. JBI Manual for Evidence Synthesis. JBI; 2024. https:\/\/doi.org\/10.46658\/JBIMES-24-06","DOI":"10.46658\/JBIMES-24-06"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tTabak GH, Akdogan N, Yel B, Gokoz O. The emergence of morphea in a patient undergoing ustekinumab therapy given for psoriasis. Dermatol Ther. 2022;35(9):e15687. https:\/\/doi.org\/10.1111\/dth.15687","DOI":"10.1111\/dth.15687"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tCorral Magana O. Morfea en una paciente con psoriasis en tratamiento con ustekinumab: \u00bfcoexistencia o efecto adverso? Actas Dermosifiliogr. 2017;108(5):486\u2013488. https:\/\/doi.org\/10.1016\/j.ad.2017.01.007","DOI":"10.1016\/j.ad.2016.11.005"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tShaffer BR, Zaino M, Bowers NL, Hunter D, Feldman SR. Morphea-like lesions after treatment with ustekinumab. Dermatol Online J. 2024;30(3):19. https:\/\/doi.org\/10.5070\/D330363882","DOI":"10.5070\/D330363882"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tLonati PA, Brembilla NC, Montanari E, et al. High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis. PLoS One. 2014;9(8):e105008. https:\/\/doi.org\/10.1371\/journal. pone.0105008","DOI":"10.1371\/journal.pone.0105008"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tDeng CC, Xu XY, Zhang Y, et al. Single-cell RNA-seq reveals immune cell heterogeneity and increased Th17 cells in human fibrotic skin diseases. Front Immunol. 2025;15:1522076. https:\/\/doi.org\/10.3389\/fimmu.2024.1522076","DOI":"10.3389\/fimmu.2024.1522076"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tSisto M, Lisi S. Interleukin-23 involved in fibrotic autoimmune diseases: new discoveries. J Clin Med. 2023;12(17):5699. https:\/\/doi.org\/10.3390\/jcm12175699","DOI":"10.3390\/jcm12175699"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tWei L, Abraham D, Ong V. The Yin and Yang of IL-17 in systemic sclerosis. Front Immunol. 2022;13:885609. https:\/\/doi. org\/10.3389\/fimmu.2022.885609","DOI":"10.3389\/fimmu.2022.885609"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tMi S, Li Z, Yang HZ, et al. Blocking IL-17A promotes resolution of pulmonary inflammation and fibrosis via TGF- \u03b21-dependent and -independent mechanisms. J Immunol. 2011;187(6):3003\u20133014. https:\/\/doi.org\/10.4049\/ jimmunol.1004081","DOI":"10.4049\/jimmunol.1004081"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tSchnell A, Littman DR, Kuchroo VK. TH17 cell heterogeneity and its role in tissue inflammation. Nat Immunol. 2023;24(1):19\u201329. https:\/\/doi.org\/10.1038\/s41590-022-01387-9","DOI":"10.1038\/s41590-022-01387-9"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tMazzoni A, Maggi L, Liotta F, Cosmi L, Annunziato F. Biological and clinical significance of T helper 17 cell plasticity. Immunology. 2019;158(4):287\u2013295. https:\/\/doi.org\/10.1111\/imm.13124","DOI":"10.1111\/imm.13124"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tMylonas A, Conrad C. Psoriasis: classical vs. paradoxical \u2014 the Yin-Yang of TNF and type I interferon. Front Immunol. 2018;9:2746. https:\/\/doi.org\/10.3389\/fimmu.2018.02746","DOI":"10.3389\/fimmu.2018.02746"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/02\/dic.2025-11-1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:27:08Z","timestamp":1791379628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/ustekinumab-associated-morphoea-systematic-review-of-the-literature-and-a-real-world-case"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7573\/dic.2025-11-1","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"article-number":"dic.2025-11-1"}}